Tony Coles
| Tony Coles M.D. | |
|---|---|
| Born | 17 May 1960 Roanoke, Virginia |
| 🏳️ Nationality | American |
| 🏫 Education | Johns Hopkins University Harvard University Duke University School of Medicine |
| 💼 Occupation | CEO of Cerevel Therapeutics |
N. Anthony Coles, also known as Tony Coles, is an American physician and the President and CEO of Cerevel Therapeutics.
Coles was the Founder and CEO of Yumanity Therapeutics, the CEO and President of Onyx Pharmaceuticals, CEO of NPS Pharmaceuticals; and has held executive positions at Vertex Pharmaceuticals, Bristol-Myers Squibb, and Merck & Co.
In 2015, Coles was made a member of the Precision Medicine Initiative team created by President Barack Obama to work with the National Institutes of Health and other bodies to promote the development of therapeutics based on individual biology.
Early life and education[edit]
Coles was born in Roanoke, Virginia, on 17 May 1960.[1]
He received a bachelor's degree from Johns Hopkins University, a Master's in Public Health from Harvard University, and an M.D. from Duke University.[2][3][4][5] Coles completed his internal medicine and cardiology residency training at Massachusetts General Hospital.[2][3][4][5] He was also a research fellow at Harvard Medical School.[2][3][4][5]
Career[edit]
From 1992 to 1996, Coles served in numerous positions with increasing responsibility at Merck & Co., Inc., including, Vice President of the Hypertension and Heart Failure Business Group.[5]
In 1996, Coles joined Bristol-Myers Squibb Company.[2][3][5] Positions that Coles held throughout his career at Bristol-Myers Squibb were: Senior Vice President of Strategy and Policy; Senior Vice President of Marketing and Medical Affairs, Neuroscience/Infectious Diseases/Dermatology; Vice President, Western Area Sales Cardiovascular and Metabolic Business Unit for U.S. Primary Care; and Vice President, Cardiovascular Global Marketing.[5] During his time with Bristol-Myers Squibb, he helped introduce cardiovascular medications such as Clopidogrel (Plavix).[1]
In 2002, Coles joined Vertex Pharmaceuticals as the Senior Vice President of Commercial Operations.[1][2][4][5] Vertex Pharmaceuticals is a global biopharmaceutical company focused on developing new treatment options for cystic fibrosis, infectious diseases, and autoimmune diseases.[6]
Coles joined NPS Pharmaceuticals in 2005 as the CEO and a member of the board of directors.[2][4][5] NPS Pharmaceuticals was a biopharmaceutical company focused on creating therapies for treating rare diseases and was acquired by Shire Pharmaceuticals in 2015.[7]
From 2008 to 2013, Coles served as the CEO, President, and Chairman of the Board of Directors of Onyx Pharmaceuticals, a biopharmaceutical company that was focused on creating cancer therapies.[3][4][5][8][9] During his tenure at Onyx Pharmaceuticals, Coles helped launch two novel cancer medicines.[3] Onyx Pharmaceuticals was acquired by Amgen in 2013.[10]
In 2014, Coles co-founded Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on developing disease-modifying agents for neurodegenerative diseases like Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis and Fronto-temporal Lobar Dementia.[11][12] He served as the President and CEO.[3][13] Coles is still a member of the Board of Directors at Yumanity Therapeutics.[4][11] Coles helped to discover new potential treatment options for Parkinson's disease and Lou Gehrig's disease.[14]
In 2015, Coles was made a member on the Board of Directors at CRISPR Therapeutics.[15][16] CRISPR Therapeutics is a biopharmaceutical company focused on developing gene-based therapies for patients with serious diseases.[15][16]
In September 2019, Coles became the President and CEO of Cerevel Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatment options for neurological diseases such as Parkinson's, Epilepsy, Alzheimer's, Schizophrenia, and addiction.[4][17] Coles also served as an Executive Chairperson of the Board of Directors since December 2018.[2]
As of 2021, Coles continues to serve as a member of the Board of Directors of McKesson Corporation and Regeneron Pharmaceuticals.[2][18][19][20]
Honors[edit]
On 9 August 2016, during the Johns Hopkins Carey Business School's commencement ceremony, Coles and his wife, Robyn, were awarded the Dean's Medal by the dean of Carey Business School, Bernard T. Ferrari.[21][22] The Dean's Medal recognizes extraordinary service, philanthropy, and leadership on behalf of Carey School of Business.[21][22]
In 2015, President Barack Obama appointed Coles to his newly created Precision Medicine Initiative team.[23] The initiative was created in an effort to develop specific disease prevention and treatment options according to the unique genes, environment, and lifestyle of a patient.[24] The main objectives of the initiative include: more and better treatments for cancer, creation of national research cohort, protecting privacy, modernizing the regulatory landscape, and creating relationships with existing research cohorts and private sectors.[24]
Community roles[edit]
Coles serves as a member of the council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the Board of Trustees for The Metropolitan Museum of Art in New York City; a member of the Board of Directors of the Council on Foreign Relations; a member of the Board of Directors of the U.S. Olympic and Paralympic Foundation, and a member of the Harvard Medical School Board of Fellows.[2][3][4][5][25][26]
Personal life[edit]
Coles is married to Robyn Coles and has three children.[1]
References[edit]
- ↑ 1.0 1.1 1.2 1.3 "Dr. N. Anthony Coles". The History Makers. Unknown parameter
|url-status=ignored (help) - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Tony Coles, M.D: Chief Executive Officer and Chairperson of the Board of Directors". Cerevel. Unknown parameter
|url-status=ignored (help) - ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "Tony Coles, M.D., M.P.H." National Institutes of Health. Unknown parameter
|url-status=ignored (help) - ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Eides, Rachel. "Cerevel Therapeutics Appoints Biotechnology Leader Tony Coles, M.D., as Chief Executive Officer". Businesswire. Unknown parameter
|url-status=ignored (help) - ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 "Tony Coles". The Pharma Letter. Unknown parameter
|url-status=ignored (help) - ↑ "Vertex Pharmaceuticals (VRTX)". Forbes. Unknown parameter
|url-status=ignored (help) - ↑ "Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech". Cision Distribution. Unknown parameter
|url-status=ignored (help) - ↑ Staton, Tracy. "Onyx CEO Tony Coles will score $58M on Amgen deal". Fierce Pharma. Unknown parameter
|url-status=ignored (help) - ↑ "Onyx Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2012 Financial Results After Market on February 21, 2013". BioSpace. Unknown parameter
|url-status=ignored (help) - ↑ Mullin, Emily. "Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer". Fierce Biotech. Unknown parameter
|url-status=ignored (help) - ↑ 11.0 11.1 "Yumanity Therapeutics". Yumanity Therapeutics. Unknown parameter
|url-status=ignored (help) - ↑ "Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model". Yahoo! Finance. Unknown parameter
|url-status=ignored (help) - ↑ Taylor, Nick. "Pfizer spinout Cerevel hires Coles as CEO". Fierce Biotech. Unknown parameter
|url-status=ignored (help) - ↑ "Tony Coles". Council on Foreign Relations. Unknown parameter
|url-status=ignored (help) - ↑ 15.0 15.1 "CRISPR Therapeutics Appoints Tony Coles, M.D., to its Board of Directors". BusinessWire. Unknown parameter
|url-status=ignored (help) - ↑ 16.0 16.1 "CRISPR Therapeutics Appoints Tony Coles, M.D., to its Board of Directors". CRISPR Therapeutics News Release. Unknown parameter
|url-status=ignored (help) - ↑ "Striving to develop new therapies for neuroscience diseases". Cerevel. Unknown parameter
|url-status=ignored (help) - ↑ "McKesson Corporation : McKesson Board of Directors Elects N. Anthony Coles as New Independent Director". MarketScreener. Unknown parameter
|url-status=ignored (help) - ↑ "Tony Coles, M.D." Regeneron: Investors & Media. Unknown parameter
|url-status=ignored (help) - ↑ "N. Anthony Coles, M.D." McKesson. Unknown parameter
|url-status=ignored (help) - ↑ 21.0 21.1 "Dean's Medal Awarded to Robyn and Tony Coles". Johns Hopkins Carey Business School. Unknown parameter
|url-status=ignored (help) - ↑ 22.0 22.1 Pulcini, Max. "Carey School of Business Dean's Medals Presented to Robyn and Tony Coles". MetroMBA. Unknown parameter
|url-status=ignored (help) - ↑ "NIH forms team of experts to chart course for the President's Precision Medicine Initiative research network". National Institutes of Health News Releases. Unknown parameter
|url-status=ignored (help) - ↑ 24.0 24.1 "FACT SHEET: President Obama's Precision Medicine Initiative". the White House Archives. Unknown parameter
|url-status=ignored (help) - ↑ "Tony Coles, MD". Black Economic Alliance. Unknown parameter
|url-status=ignored (help) - ↑ "USOPF BOARD OF DIRECTORS". Team USA: U.S. Olympic & Paralympic Foundation. Unknown parameter
|url-status=ignored (help)
[[Category:]]
This article "Tony Coles" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Tony Coles. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
